least 12 groups (I-XII) comprising 16 individual PLA 2 (29) . Historically, a PLA 2 is classified on the basis of whether it is secreted from the cell (secretory PLA 2 ), Ca 2ϩ dependent and located in the cytosol (cPLA 2 ), or Ca 2ϩ independent (iPLA 2 ). cPLA 2 (groups IVA-B) is one of the most widely studied and is found in the cytosol of many types of cells, including the pancreas, heart, and kidney (6, 7) . cPLA 2 requires micromolar amounts of Ca 2ϩ to facilitate translocation to cellular membranes on activation but does not require Ca 2ϩ for its catalytic activity. cPLA 2 range in size from 85 to 100 kDa (7) . iPLA 2 (groups IVC, VI, VIIB, and VIII) does not require Ca 2ϩ , ranges in molecular size from 29 to 85 kDa, and typically is found in the cytosol. A key difference between cPLA 2 and iPLA 2 is that iPLA 2 is inhibited by the suicide substrate (E)-6-(bromoethylene)-3-(1-naphthaleny)-2H-tetrahydropyran-2-one [or bromoenol lactone (BEL)], whereas cPLA 2 is not. This fact has been used in a number of studies to distinguish between cPLA 2 and iPLA 2 activities (1, 10) . In addition, iPLA 2 can be distinguished from cPLA 2 activity on the basis of its selectivity for phospholipid substrates and Ca 2ϩ requirement. A number of iPLA 2 activities have been described in a variety of tissues, including those of hamsters (32) , mice (4), rats (4) , and humans (14, 15) . To date, the best characterized iPLA 2 from all species is an 85-kDa protein that is inhibited by BEL and is present in multiple isoforms, a result of alternative splicing. This iPLA 2 is commonly called iPLA 2 ␤ and is cytosolic. Recently, Mancuso et al. (16) and Tanaka et al. (31) have characterized novel membrane-associated iPLA 2 that share 91% DNA sequence homology to each other, but only limited homology to iPLA 2 ␤, confined to the ATP-binding motif and the lipase site. This iPLA 2 has been termed iPLA 2 ␥. Mancuso et al. (16) demonstrated that translation of the DNA sequence for iPLA 2 ␥ in insect Sf-9 cells resulted in the expression of two proteins with molecular masses of 67-77 kDa. Activity and expression of these proteins localized to membrane fractions and were inhibited by BEL. In contrast, Tanaka et al. (31) reported that translation of a candi-date iPLA 2 ␥ sequence in bacterial COS-7 cells resulted in one 85-kDa protein whose expression and activity also localized to membrane fractions. The activity of this 85-kDa iPLA 2 was inhibited by BEL. The only other reported iPLA 2 expressed in the membrane is an 80-kDa iPLA 2 expressed in the plasma membrane of cardiomyocytes (17) .
The above studies did not examine membrane-bound iPLA 2 protein or activity in mammalian cells, determine the selectivity of iPLA 2 for specific phospholipids, or determine the membrane location in which it was expressed. In addition, a physiological role for this iPLA 2 was not addressed. In this study, we investigated an iPLA 2 in renal proximal tubular cells (RPTC) with respect to expression, subcellular localization, inhibition profile, and selectivity for specific phospholipid substrates. In addition, we tested the hypothesis that iPLA 2 plays a role in mediating oxidant-induced renal cell oncosis and lipid peroxidation.
MATERIALS AND METHODS

Materials.
Female New Zealand White rabbits (1.5-2.0 kg) were purchased from Myrtle's Rabbitry (Thompson Station, TN). L-Ascorbic acid-2-phosphate (magnesium salt) was obtained from Wako Chemicals (Richmond, VA). The antibody to iPLA 2␤ was purchased from Cayman Chemical (Ann Arbor, MI), and annexin V-FITC was obtained from R&D Systems (San Diego, CA). The antibody to the heat shock protein GRP78 was purchased from Calbiochem (La Jolla, CA), and the antibody against the peroxisomal protein PMP70 was obtained from Affinity BioReagents (Golden, CO). The endoplasmic reticulum (ER) and DNA stains (DiOC6)3 and 4,6-diamidino-2-phenylindole were obtained from Molecular Probes (Eugene, OR). Cisplatin, propidium idodide, duraquinone, menadione, antimycin A, tert-butylhydroperoxide (TBHP), cumene hydroperoxide, and all other chemicals were purchased from Sigma (St. Louis, MO).
Isolation of proximal tubules and culture conditions. Rabbit RPTC were isolated using the iron oxide perfusion method and grown in 35-mm tissue culture dishes under improved condition, as previously described (21, 22) . The cell culture medium was a 1:1 mixture of DMEM/Ham's F-12 (without D-glucose, phenol red, or sodium pyruvate) supplemented with 15 mM HEPES buffer, 2.5 mM L-glutamine, 1 M pyridoxine HCl, 15 mM sodium bicarbonate, and 6 mM lactate. Hydrocortisone (50 nM), selenium (5 ng/ml), human transferrin (5 g/ml), bovine insulin (10 nM), and L-ascorbic acid-2-phosphate (50 M) were added to fresh culture medium immediately before daily media change.
Immunoblot analysis. Microsomal and cytosolic fractions were isolated from RPTC as previously described (17) . Immunoblot analysis of both microsomal and cytosolic protein (20 g) from RPTC was performed as described previously using a polyclonal rabbit anti-iPLA2 antibody that recognizes 85-kDa iPLA2␤ (17) .
Immunocytochemical analysis. Immunocytochemical analysis of iPLA2, ER, peroxisomes, and nuclei staining were performed using confocal laser scanning microscopy. Confluent RPTC monolayers were washed with PBS, fixed in 3.7% formaldehyde, and permeabilized with 0.1% (vol/vol) Triton X-100. Nonspecific binding was blocked using 8% BSA, and RPTC were incubated overnight with a goat anti-rabbit polyclonal antibody to 85-kDa iPLA2␤ (100-fold dilution) followed by exposure to a secondary antibody (1,000-fold dilution) conjugated to either a 480/510-or 535/610-nm excitation/ emission fluorochrome. For colocalization studies, RPTC were exposed to markers of the ER [(DiOC 6)3 or GRP78 antibody] or the peroxisomes (PMP70 antibody). Nuclei were stained using 4,6-diamidino-2-phenylindole (350/390-nm excitation/emission). Secondary antibodies for both GRP78 and PMP70 were conjugated to a 480/510-nm excitation/emission fluorochrome. After the final wash, RPTC were covered with mounting media and coverslips. Staining was visualized with a 410 Zeiss confocal laser scanning microscope.
Measurement of PLA 2 activity. PLA2 activity was determined under linear conditions in microsomes and cytosol as described previously (18) . Activity was measured by using synthetic (16:0, [ 3 H]18:1) plasmenylcholine and phosphatidylcholine substrates (100 M) in the absence of Ca 2ϩ (presence of 4 mM EGTA). For PLA2 activity inhibition studies, confluent RPTC were exposed to either a solvent control [DMSO Ͻ0.1% (vol/vol)] or 1-10 M BEL for 30 min.
Measurement of oncosis. Oncosis was monitored by assessment of both annexin V (a marker for apoptosis) and propidium iodide (PI; a marker for oncosis) staining using flow cytometry. Briefly, RPTC were exposed to the oxidants TBHP (200 M), cumene hydroperoxide (200 M), duraquinone (400 M), and cisplatin (400 M) for 24 h and to menadione (10 M) for 12 h. In addition RPTC were exposed to the nonoxidant antimycin A (0.3 M) for 4 h. Annexin and PI staining were monitored using confocal laser scanning microscopy and flow cytometry as described previously, with modifications (9, 19, 28) . After treatment, the medium was removed, and RPTC were washed twice and incubated in binding buffer [(in mM) 10 HEPES, 140 NaCl, 5 KCl, 1 MgCl 2, 1.8 CaCl2, pH ϭ 7.4] containing annexin V-FITC (2.5 g/ml) and PI (25 g/ml). Cells were washed three times in binding buffer and prepared for either flow cytometry or microscopy. For flow cytometry, RPTC were released from the monolayer by using a rubber policeman, and staining was quantified by using a Becton Dickinson FacsCalibur flow cytometer. Minimal binding of annexin V in the absence of PI staining was detected in these samples (Ͻ10%), demonstrating that the major mode of cell death was oncosis.
Measurement of lipid peroxidation. Lipid peroxidation in RPTC was monitored as the production of malondialdehyde (MDA) as described previously (26) . RPTC were treated with the indicated compound for 2 h and isolated by scraping the dish with a rubber policeman. RPTC suspensions were treated with 10% trichloroacetic acid and centrifuged, the supernatant was removed, and it was combined with 2-thiobarbituric acid (0.76%), heated, cooled, and absorbance measured at 532 nm with 1,1,3,3-tetraethoxypropane as a standard.
Statistical analysis. RPTC isolated from one rabbit represent one experiment (n ϭ 1). The appropriate ANOVA was performed for each data set by using SigmaStat statistical software. Individual means were compared with Fisher's protected least significant difference test with P Յ 0.05 being considered a statistically significant difference between mean values. Linear regression was also performed by using Sigma Stat statistical software. 2 in RPTC. Microsomal and cytosolic fractions from confluent cultures of RPTC were subjected to immunoblot analysis using a primary antibody that recognizes cytosolic 85-kDa iPLA 2 ␤. This antibody recognized a single band in immunoblots of microsomal protein from RPTC and comigrated with purified iPLA␤ (a gift from Genetics Institute, Cambridge, MA). No band was detected in immunoblots of cytosolic RPTC protein (Fig. 1) . No staining was detected in the IgG control. These data show that a protein with sequence homology to iPLA 2 ␤, a cytosolic protein, is expressed in RPTC microsomal fractions.
RESULTS
Expression and activity of iPLA
Because immunoblot analysis suggested that RPTC iPLA 2 was expressed in the ER, the colocalization of iPLA 2 with markers of the ER, peroxisomes, and mitochondria was determined. Immunocytochemistry and confocal laser scanning microscopy of fixed RPTC revealed punctate staining as opposed to cytosolic staining, with little staining in the nucleus (Fig. 2, A-C) . No staining was detected in the IgG control (data not shown). Staining of iPLA 2 was similar to the staining of the ER markers (DiOC 6 )3 (Fig. 2, A-C) and GRP78 (Fig. 2, D-F) . In contrast, the staining pattern of the peroxisomal marker protein PMP70 and iPLA 2 was different, with minimal colocalization observed (Fig. 2,  G-I) . No staining, other than that for iPLA 2 , was observed in dishes incubated with primary and secondary antibodies to iPLA 2 followed by secondary antibodies to GRP78 and PMP70 (data not shown). No colocalization was observed between iPLA 2 and the mitochondrial stain Mitotracker green (data not shown).
The activity of iPLA 2 in microsomes and cytosol from RPTC was measured to further investigate the membrane localization and characterize ER-iPLA 2 (Fig. 3) . iPLA 2 activity was measured by the release of in the microsomal fraction was ϳ12,000 pmol⅐min Ϫ1 ⅐mg protein Ϫ1 compared with ϳ1,000 pmol⅐min Ϫ1 ⅐mg protein Ϫ1 in the cytosolic fraction. ER-iPLA 2 demonstrated a preference for plasmenylcholine compared with phosphatidylcholine, whereas no preference was detected in the cytosol. Treatment of RPTC with BEL before microsomal isolation resulted in a concentration-dependent decrease in iPLA 2 activity, with 3 M BEL resulting in Ͼ50% inhibition and 5 M BEL resulting in Ͼ90% inhibition of iPLA 2 activity. In contrast, methyl arachidonyl fluorophosphonate (MAFP) and arachidonyl trifluoromethyl ketone (AAOCF 3 ), two cPLA 2 inhibitors, did not inhibit ER-iPLA 2 at similar concentrations. At higher concentrations, 10 M MAFP only decreased phosphatidylcholine hydrolysis by 20% in microsomes and had no effect on plasmenylcholine hydrolysis. Similarly, AAOCF 3 only decreased ER-iPLA 2 activity at concentrations of 20 M or higher. Collectively, these data demonstrate the expression and activity of an 85-kDa ER-iPLA 2 in RPTC that preferentially hydrolyzes plasmalogens and is specifically inhibited by BEL.
Role of ER-iPLA 2 in RPTC cell death. Little is known concerning the role of iPLA 2 , particularly ER-iPLA 2, in cell injury and death. To test the hypothesis that ERiPLA 2 plays a role in RPTC oxidant-induced cell death, RPTC were treated with either solvent control [DMSO at Ͻ 0.1% (vol/vol)] or BEL (5 M) before 2-, 4-, 12-, and 24-h exposures to 200 M TBHP. TBHP caused timedependent increases in cell death, resulting in ϳ20% oncosis at 24 h (Fig. 4) . TBHP also induced concentration-dependent cell death, with a concentration of 500 M resulting in 69 Ϯ 3% oncosis after 24 h. The level of oncosis in controls was ϳ2-3% and remained constant over time. Confocal microscopy confirmed the timedependent increase in oncosis (data not shown). Treatment of cells with BEL before exposure to TBHP potentiated oncosis at all time points. Linear regression analysis revealed a strong correlation (r 2 ϭ 0.98) between BEL inhibition of ER-iPLA 2 activity and BEL potentiation of TBHP-induced oncosis (Fig. 5) . These data suggest a direct link between ER-iPLA 2 inhibition and potentiation of oxidant-induced oncosis. Studies were conducted to determine whether the potentiating effects of BEL on TBHP-induced oncosis occurred with other oxidants. The chemotherapeutic agent cisplatin is nephrotoxic and thought to produce renal cell death, in part, through oxidative stress (30, 36) . Treatment of RPTC with cisplatin for 24 h resulted in 40% oncosis, and prior inhibition of ER-iPLA 2 with BEL increased oncosis 1.5-fold (Fig. 6) . The model oxidants cumene hydroperoxide, duraquinone, and menadione produced 10-50% RPTC oncosis after 24, 24, and 12 h of exposure, respectively (Fig. 6 ). Similar to TBHP and cisplatin, pretreatment of RPTC with BEL potentiated the degree of oncosis induced by all of these oxidants 1.5-to 3.3-fold. Antimycin A, a mitochondrial inhibitor, is used as a model of anoxia and produces RPTC oncosis without causing oxidative stress (27) . Treatment of RPTC with 0.3 M antimycin A for 4 h resulted in 50% oncosis and, unlike any of the oxidants used, pretreatment of RPTC with BEL did not increase oncosis over that of RPTC treated with antimycin A alone. Thus oncosis induced by five diverse oxidants was potentiated by inhibition of ER-iPLA 2 , whereas that of a nonoxidant was not.
Role of ER-iPLA 2 in oxidant-induced lipid peroxidation. We hypothesized that the potentiation of oncosis caused by ER-iPLA 2 inhibition was the result of increased retention of peroxidized phospholipids during oxidative stress. To test this hypothesis, RPTC were pretreated with BEL (5 M) or solvent control [DMSO at Ͻ0.1% (vol/vol)] and exposed to TBHP, cisplatin, cumene hydroperoxide, menadione, duraquinone, and antimycin A for 2 h. No cell death was evident in RPTC treated with oxidants at this time. Basal levels of MDA formation in control RPTC were 0.3 nmol/mg, and treatment of RPTC with BEL did not increase this value (Fig. 7) . Treatment of RPTC with oxidants or antimycin A for 2 h did not increase MDA formation above control. Longer exposures of cells to oxidants, but not antimycin A, did result in increased MDA formation (data not shown). In contrast to oxidants alone, treatment of RPTC with BEL before oxidant exposure produced MDA formation. Treatment of RPTC with BEL before exposure to antimycin A did not increase MDA formation.
DISCUSSION
In the past few years, a number of PLA 2 have been identified and progress has been made in elucidating the functions of many types of PLA 2 , especially cPLA 2 . However, iPLA 2 are incompletely explored, and their physiological and pathological functions remain under investigation. For example, iPLA 2 ␤ is a cytosolic 85-kDa PLA 2 that is expressed in the pancreas, heart, brain, and macrophages (5, 6, 14, 15, 24, 34) . It also has been demonstrated to exist as multiple proteins as a result of alternative splicing (15) . In normally functioning cells, iPLA 2 ␤ has been suggested to mediate phospholipid remodeling by means of mechanisms that are not fully determined (34) . iPLA 2 ␤ also may mediate cell death induced by Fas ligand and hypoxia (2, 3, 35) .
Recently, Mancuso et al. (16) and Tanaka et al. (31) , using sequences derived from the human genome project, identified, sequenced, cloned, and expressed a novel iPLA 2 (iPLA 2 ␥) in insect and bacterial cells. iPLA 2 ␥ is similiar in size to iPLA 2 ␤ and an iPLA 2 found in the plasma membrane of myocytes (17) but is expressed in intracellular membranes. Neither Mancuso et al. (16) nor Tanaka et al. (31) determined the specific intracellular membrane in which iPLA 2 ␥ is expressed, its preference for specific phospholipids, or its physiological function within the cell. We report for the first time the expression of an 85-kDa iPLA 2 in primary cultures of kidney cells whose activity and expression were in microsomes, demonstrated selectivity for plasmalogen phospholipids, and were inhibited by BEL. This ER-iPLA 2 appears to be constitutively expressed in microsomal membranes, because freshly isolated cells had the same iPLA 2 expression and activity as primary cultures (data not shown). The ER location of RPTC iPLA 2 is not the result of translocation of iPLA 2 ␤ to the membrane during isolation or culture. First, no immunoreactive band was detected in the cytosolic fractions isolated from these cells at any time point of isolation or treatment. Immunocytochemistry of untreated cells, using the same antibody used for immunoblot analysis, demonstrated that iPLA 2 was expressed in a punctate manner similar to proteins localized to the ER membrane as opposed to those expressed in the cytosol. On the basis of the similarities in membrane expression, size, activity, and inhibition profile, we propose that ER-iPLA 2 is the rabbit iPLA 2 ␥.
The majority of iPLA 2 activity in RPTC was present in the microsomal fraction and displayed substrate selectivity for plasmenylcholine over phosphatidylcholine. A small amount of iPLA 2 activity was detected in the cytosolic fraction (ϳ1,000 pmol/mg), which may represent the 28-kDa cytosolic iPLA 2 or a small amount of ER contamination (23) . BEL resulted in 90% inhibition of plasmenylcholine hydrolysis and totally inhibited phosphatidylcholine hydrolysis by RPTC ERiPLA 2 . Neither AAOCF 3 nor MAFP inhibited RPTC ER-iPLA 2 activity at concentrations under 10 M and only minimally inhibited activity at higher concentrations. Thus RPTC ER-iPLA 2 activity is specifically inhibited by BEL as opposed to AAOCF 3 or MAFP. RPTC ER-iPLA 2 decreased sensitivity to inhibition by AAOCF 3 and MAFP compared with BEL is different from the inhibition profile seen for iPLA 2 ␤ (6). These differences may be a result of the membrane location of ER-iPLA 2 or may reflect variations in key amino acids in the active sight of each enzyme.
The role of cPLA 2 and secretory PLA 2 in cellular physiology and injury is well established (3, 6, 20, 25) . In comparison, the role of iPLA 2 in normal cell physiology and injury is not as well characterized. In contrast to iPLA 2 ␤, nothing is known concerning the role of ER-iPLA 2 in normal cell physiology and cell injury and death. Data presented in this study suggest that ER-iPLA 2 protects against oxidative-induced cell death. Inhibition of ER-iPLA 2 using BEL potentiated oncosis induced by each oxidant used in this study but not that of a nonoxidant. The increase in oxidantinduced RPTC oncosis after inhibition of ER-iPLA 2 correlated with increases in lipid peroxidation early in the genesis of oncosis. Finally, a strong correlation exists between the percent inhibition of ER-iPLA 2 with BEL and potentiation of cell death by BEL (r 2 ϭ 0.98), suggesting that these events are linked. Thus we conclude that the potentiation of oxidant-induced oncosis in RPTC is a result of inhibition of ER-iPLA 2 .
Studies on the role of ER-iPLA 2 in cell death were conducted with the previously characterized iPLA 2 -inhibitor BEL. In the absence of an alternative method to inhibit ER-iPLA 2 , we verified that the potentiation of oxidant-induced cell death in the presence of BEL was not the result of decreases in cellular GSH, ATP, GTP, and oxygen consumption levels (data not shown).
MDA is an end product of lipid peroxidation, which itself is a result of a free radical attack on an unsaturated double bond of a phospholipid (i.e., initiation) (33) . The free radical propagates from one phospholipid to another and eventually leads to the formation of smaller lipid fragments, one of which is MDA. The reaction is stopped or terminated when the free radical is quenched or when it is removed from the site of injury. We propose that oxidant-induced lipid peroxidation results in enhanced metabolism of phospholipids by ER-iPLA 2 . Metabolism of peroxidized phospholipids by ER-iPLA 2 would cleave and remove these damaging species before their conversion to MDA and prohibit propagation of the free radical. If this model is correct, then inhibition of ER-iPLA 2 with BEL would result in an increase in lipid peroxides before increases in cell death.
In conclusion, we have identified and characterized a novel ER-iPLA 2 that is similar to iPLA 2 ␥ but distinct from iPLA 2 ␤ in that it is expressed at an intracellular membrane and inhibited specifically by BEL. Inhibition of RPTC ER-iPLA 2 during oxidant-induced renal cell oncosis resulted in an increase in the level of lipid peroxides, suggesting that this enzyme may play a key role in the metabolism and removal of these damaging species during injury induced by diverse stimuli. Collectively, these data suggest that ER-iPLA 2 plays a protective role during oxidative stress by removing oxidized phospholipids. 
